- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05119465
COVID-19 Clinical Status Associated With Outcome Severity: An Unsupervised Machine Learning Approach
Does Corona Virus Disease (COVID)-19 Clinical Status Associates With Outcome Severity?An Unsupervised Machine Learning Approach for Knowledge Extraction
Since the beginning of the COVID-19 pandemic, 195 million people have been infected and 4.2 million have died from the disease or its side-effects. Physicians, healthcare scientists and medical staff continuously try to deal with overloaded hospital admissions, while in parallel, they try to identify meaningful correlations between the severity of infected patients with their symptoms, comorbidities and biomarkers. Artificial Intelligence (AI) and Machine Learning (ML) have been used recently in many areas related to COVID-19 healthcare. The main goal is to manage effectively the wide variety of issues related to COVID-19 and its consequences. The existing applications of ML to COVID-19 healthcare are based on supervised classification which require a labeled training dataset, serving as reference point for learning, as well as predefined classes. However, the existing knowledge about COVID-19 and its consequences is still not solid and the points of common agreement among different scientific communities are still unclear.
Therefore, this study aimed to follow an unsupervised clustering approach, where prior knowledge is not required (tabula rasa).
More specifically, 268 hospitalized patients at the First Propaedeutic Department of Internal Medicine of AHEPA University Hospital of Thessaloniki were assessed in terms of 40 clinical variables (numerical and categorical), leading to a high-dimensionality dataset. Dimensionality reduction was performed by applying Principal Component Analysis (PCA) on the numerical part of the dataset and Multiple Correspondence Analysis (MCA) on the categorical part of the dataset. Then, the Bayesian Information Criterion(BIC) was applied to Gaussian Mixture Models (GMM) in order to identify the optimal number of clusters, under which, the best grouping of patients occurs.
The proposed methodology identified 4 clusters of patients with similar clinical characteristics. The analysis revealed a cluster of asymptomatic patients that resulted in death at a rate of 23.8%.
This striking result forces us to reconsider the relationship between the severity of COVID-19 clinical symptoms and patient's mortality.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Thessaloníki, Greece, 54621
- University General Hospital of Thessaloniki AHEPA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients that came into emergency department and diagnosed with COVID-19 infection
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Group
Hospitalized Patients with Corona virus disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cluster of patients depending on severity of infection
Time Frame: 1 year
|
Algorithm produced with artificial intelligence and machine learning approach to classify patients according their status of COVID-19 infection
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19400_21052021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.